Model-Based Approach for Optimizing Ceftobiprole Dosage in Pediatric Patients

por Rubino, Christopher M., Cammarata, Anthony P., Smits, Anne, Schröpf, Sebastian, Polak, Mark, Litherland, Karine, Hamed, Kamal
Publicado 2021

2549. Pharmacometric Analyses to Support Sulbactam-Durlobactam (SUL-DUR) Dosing Regimens in Patients with Altered Renal Function

por Larson, Kajal, Bhavnani, Sujata M, Hammel, Jeffrey P, Cammarata, Anthony P, O’Donnell, John, Rubino, Christopher M
Publicado 2023

2561. Population Pharmacokinetic Analyses for Ceftobiprole Using Data from Phase 1 and 3 Studies

por Cammarata, Anthony P, Litherland, Karine, Safir, M Courtney, Bhavnani, Sujata M, Saulay, Mikael, Smart, Jennifer, Jones, Mark E, Engelhardt, Marc, Rubino, Christopher M
Publicado 2023

2532. Pharmacokinetic-Pharmacodynamic Analyses for Ceftobiprole Efficacy Based on Phase 3 Data from Patients with Staphylococcus aureus Bacteremia

por Bhavnani, Sujata M, Hammel, Jeffrey P, Liolios, Kathryn, Cammarata, Anthony P, Saulay, Mikael, Rubino, Christopher M, Engelhardt, Marc, Smart, Jennifer, Jones, Mark E, Ambrose, Paul G, Litherland, Karine
Publicado 2023

LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam...

por Bhavnani, Sujata M, Bhavnani, Sujata M, Bhavnani, Sujata M, Rubino, Christopher M, Hammel, Jeffrey P, Cammarata, Anthony P, Larson, Kajal, Liolios, Kathryn, McLeod, Sarah, Miller, Alita, Ambrose, Paul G, Tommasi, Ruben, O'Donnell, John
Publicado 2022